Rheumatoid arthritis autoimmune reaction

Immune defense mechanisms can become deleterious for an individual when they are not controlled properly. Then they can cause disease. In such situations therapy is aimed to dampen immune reactions. Important examples are sqttic shock, allergy, autoimmune diseases, and chronic inflammatory diseases such as rheumatoid arthritis. Also, the success of organ transplantation... 

It is a cyclic polypeptide with 11 amino acids. It selectively inhibits T-lymphocytes proliferation, IL-2 and other cytokine production. It is the most effective drug for prevention and treatment of graft rejection reaction. It is used in cardiac, hepatic, renal, bone marrow transplantation and as second line drug in rheumatoid arthritis, inflammatory bowel disease, dermato-myositis, bronchial asthma and certain other autoimmune diseases. 

Until the role of echinacea in immune modulation is better defined, this agent should be avoided in patients with immune deficiency disorders (eg, AIDS, cancer), autoimmune disorders (eg, multiple sclerosis, rheumatoid arthritis), and patients with tuberculosis. While there are no reported drug interactions for echinacea, some preparations have a high alcohol content and should not be used with medications known to cause a disulfiram-like reaction. In theory, echinacea should also be avoided in persons taking immunosuppressant medications (eg, organ transplant recipients). 

Type III Reactions These reactions involve the presence of antigen-antibody complexes, particularly those formed as a result of the production of autoantibodies. These complexes deposit in various tissues and involve inflammatory cells as well as complement, resulting in tissue damage due to the production of proteolytic enzymes by polymorphonuclear leukocytes and macrophages. A number of autoimmune diseases result from these reactions. Some clinical examples include systemic lupus erythematosus, rheumatoid arthritis, immune complex glomerulonephritis, Arthus reaction and serum sickness. 

Despite a good overall safety profile, anti-TNF antibodies can induce a number of adverse effects, including autoimmunity and infections. A trial in the treatment of Crohn s disease noted infusion reactions, transient increased of anti-dsDNA antibodies, and serum sickness-like delayed hypersensitivity with retreatment. Induction of human-antichimeric-antibodies was suggested as the cause of some of the infusion reactions [90]. A prospective study in 35 patients with Crohn s disease showed induction of ANA and anti-dsDNA autoantibodies in 53% and 35% of infliximab-treated patients [91]. A single patient showed clinical features consistent with drug-induced lupus, including the presence of ANA and anti-dsDNA autoantibodies, which quickly resolved after discontinuation of infliximab. Reports on renal adverse effects of anti-TNF antibodies are very rare. Saint Marcoux described the occurrence of crescentic GN in as few as 2 patients out of a cohort of 39 patients, treated with an anti-TNF antibody for rheumatoid arthritis [92]. A case report by Chin et al. [93] described the case of a 29-year-old Australia-born Vietnamese who presented with nephrotic syndrome. A renal biopsy showed membranous nephropathy. Symptoms attenuated after discontinuation of infliximab therapy. 

Photophoresis is a variant of PUVA treatment (Edelson et al., 1987 Horio, 2000). Leukocytes from patients with cutaneous T-cell lymphoma or autoimmune disorders (rheumatoid arthritis and systemic sclerosis) are exposed to UVA radiation in the presence of a psoralen and given back to the patients. It is believed that PUVA changes some surface markers of T-cells and thus triggers the immune system. Thus, this treatment can be regarded as a beneficial application of a photoallergic reaction. 

Infliximab is indicated for the treatment of rheumatoid arthritis in combination with methotrexate and for Crohn s disease. Long-term use may be associated with the development of anti-infliximab antibodies, an effect that does not appear when it is used with methotrexate. Warnings associated with the use of infliximab include risks of autoimmunity, infections, and hypersensitivity reactions. An excellent review of the properties and use of infliximab has recently appeared (84). Infliximab is more specific than etanercept, because etanercept binds to both TNFa and TNFp whereas infliximab is an antibody that binds only to TNFa. Infliximab possesses a longer half-life giving a dosing schedule of approximately every 6 to 8 weeks. 

D-Fructosamine undergoes Buchi cyclocondensation reaction with nitriles, providing access to a variety of disubstituted imidazoles (Scheme 45), some of which have been proposed as potential sphingosine-1-phosphate lyase inhibitors for the treatment of such autoimmune disorders as rheumatoid arthritis or multiple sclerosis. 

C44H69NO12, Mr 804.04, prisms, mp. 127-129°C, [ajj, -84.4° (CHCI3), a macrolactam lactone produced by Streptomyces tsukubaensis, in which a long-chain hy-droxycarboxylic acid is cyclized with L- pipecoUc acid as bridging unit. FK-506 is structurally related to rapamycin and has been prepared synthetically. It exhibits immunosuppressive activity by suppression of cell-mediated and humoral immune responses. It has been available in Japan since 1993, in Europe and USA since 1996 under the name Prograf tacrolimus) for use in transplantation medicine to suppress rejection reactions. FK-506 is also effective in the treatment of autoimmune diseases, e. g., multiple sclerosis, psoriasis, or rheumatoid arthritis. 

In addition, silicone-containing medical devices, particularly breast prostheses, have been reported to cause serum-sickness-like reactions, scleroderma-like lesions, and an SLE-like disease termed human adjuvant disease [11,23]. Some patients may also present with granulomas and autoantibodies. Human adjuvant disease is a coimective tissue or autoimmune disease similar to that of adjuvant arthritis in rats and rheumatoid arthritis in humans. Autoimmime disease-like symptoms usually develop 2-5 y after implantation in a small percentage of people that receive implants, which may indicate that there is a genetic predisposition similar to that for... 

---